BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Coppola N, Marrone A, Pisaturo M, Starace M, Signoriello G, Gentile I, Adinolfi LE, Sagnelli E, Zampino R. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis. 2014;33:559-567. [PMID: 24081499 DOI: 10.1007/s10096-013-1985-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 McKay LGA, Thomas J, Albalawi W, Fattaccioli A, Dieu M, Ruggiero A, McKeating JA, Ball JK, Tarr AW, Renard P, Pollakis G, Paxton WA. The HCV Envelope Glycoprotein Down-Modulates NF-κB Signalling and Associates With Stimulation of the Host Endoplasmic Reticulum Stress Pathway. Front Immunol 2022;13:831695. [PMID: 35371105 DOI: 10.3389/fimmu.2022.831695] [Reference Citation Analysis]
2 Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Paparo SR, Patrizio A, Mazzi V, Colaci M, Giuggioli D, Ferri C, Antonelli A. Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C? J Immunol Res 2019;2019:5878960. [PMID: 31485460 DOI: 10.1155/2019/5878960] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
3 Mavilia MG, Wu GY. HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation. J Clin Transl Hepatol 2018;6:296-305. [PMID: 30271742 DOI: 10.14218/JCTH.2018.00016] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 11.5] [Reference Citation Analysis]
4 Abutaleb A, Kottilil S. Vedroprevir in the management of hepatitis C virus infection. Expert Opin Investig Drugs 2017;26:1399-402. [PMID: 29053394 DOI: 10.1080/13543784.2017.1395412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Xiong H, Rong X, Wang M, Xu R, Huang K, Liao Q, Huang J, Chen J, Li C, Tang X, Shan Z, Zhang M, Nelson K, Fu Y. HBV/HCV co-infection is associated with a high level of HCV spontaneous clearance among drug users and blood donors in China. J Viral Hepat 2017;24:312-9. [PMID: 27943542 DOI: 10.1111/jvh.12644] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
6 Gentile I, Scotto R, Zappulo E, Buonomo AR, Pinchera B, Borgia G. Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. Expert Opinion on Investigational Drugs 2016;25:557-72. [DOI: 10.1517/13543784.2016.1161023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
7 Coppola N, Onorato L, Pisaturo M, Macera M, Sagnelli C, Martini S, Sagnelli E. Role of occult hepatitis B virus infection in chronic hepatitis C. World J Gastroenterol 2015; 21(42): 11931-11940 [PMID: 26576082 DOI: 10.3748/wjg.v21.i42.11931] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
8 Gentile I, Maraolo AE, Buonomo AR, Zappulo E, Borgia G. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opin Drug Discov. 2015;10:1363-1377. [PMID: 26563720 DOI: 10.1517/17460441.2015.1094051] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
9 Coppola N, Pisaturo M, Zampino R, Macera M, Sagnelli C, Sagnelli E. Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. World J Gastroenterol 2015; 21(38): 10749-10759 [PMID: 26478667 DOI: 10.3748/wjg.v21.i38.10749] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
10 Esmail MA, Hassuna NA, Amr KS, Ghazawy ER, Abdel-Hamid M. Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients. J Med Virol 2016;88:481-6. [PMID: 26280154 DOI: 10.1002/jmv.24354] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
11 Zampino R, Coppola N, Cirillo G, Boemio A, Grandone A, Stanzione M, Capoluongo N, Marrone A, Macera M, Sagnelli E, Adinolfi LE, del Giudice EM. Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B. Dig Dis Sci 2015;60:3005-10. [DOI: 10.1007/s10620-015-3716-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
12 Gentile I, Buonomo AR, Zappulo E, Borgia G. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Expert Rev Anti Infect Ther 2014;12:763-73. [PMID: 24918116 DOI: 10.1586/14787210.2014.929497] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
13 Coppola N, Sagnelli C, Pisaturo M, Minichini C, Messina V, Alessio L, Starace M, Signoriello G, Gentile I, Filippini P, Sagnelli E. Clinical and virological characteristics associated with severe acute hepatitis B. Clin Microbiol Infect. 2014;20:O991-O997. [PMID: 24930916 DOI: 10.1111/1469-0691.12720] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
14 Gentile I, Buonomo AR, Zappulo E, Borgia G. Discontinued drugs in 2012 – 2013: hepatitis C virus infection. Expert Opinion on Investigational Drugs 2015;24:239-51. [DOI: 10.1517/13543784.2015.982274] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
15 Zampino R, Coppola N, Cirillo G, Boemio A, Minichini C, Marrone A, Stanzione M, Starace M, Durante-Mangoni E, Sagnelli E, Restivo L, Salzillo G, Fascione MC, Nevola R, Giudice EMD, Adinolfi LE. Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. World J Hepatol 2014; 6(9): 677-684 [PMID: 25276284 DOI: 10.4254/wjh.v6.i9.677] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
16 Gentile I, Buonomo AR, Borgia G. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Rev Anti Infect Ther. 2014;12:1033-1043. [PMID: 25074011 DOI: 10.1586/14787210.2014.940898] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
17 Gentile I, Buonomo AR, Zappulo E, Minei G, Morisco F, Borrelli F, Coppola N, Borgia G. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther Clin Risk Manag. 2014;10:493-504. [PMID: 25061308 DOI: 10.2147/tcrm.s66731] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
18 Coppola N, Zampino R, Sagnelli C, Bellini G, Marrone A, Stanzione M, Capoluongo N, Boemio A, Minichini C, Adinolfi LE. Cannabinoid receptor 2-63 QQ variant is associated with persistently normal aminotransferase serum levels in chronic hepatitis C. PLoS One. 2014;9:e99450. [PMID: 24940753 DOI: 10.1371/journal.pone.0099450] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
19 Sagnelli E, Sagnelli C, Pisaturo M, Coppola N. Hepatic flares in chronic hepatitis C: Spontaneous exacerbation vs hepatotropic viruses superinfection. World J Gastroenterol 2014; 20(22): 6707-6715 [PMID: 24944463 DOI: 10.3748/wjg.v20.i22.6707] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
20 Gentile I, Borgia G. Vertical transmission of hepatitis B virus: challenges and solutions. Int J Womens Health. 2014;6:605-611. [PMID: 24966696 DOI: 10.2147/ijwh.s51138] [Cited by in Crossref: 10] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
21 Gentile I, Coppola N, Buonomo AR, Zappulo E, Borgia G. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opin Investig Drugs. 2014;23:1211-1223. [PMID: 24848437 DOI: 10.1517/13543784.2014.921680] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
22 Gentile I, Zappulo E, Buonomo AR, Borgia G. Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus. Expert Rev Anti Infect Ther. 2014;12:775-782. [PMID: 24840817 DOI: 10.1586/14787210.2014.920254] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
23 Sagnelli E, Pisaturo M, Martini S, Sagnelli C, Filippini P, Coppola N. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. Expert Opin Pharmacother. 2014;15:1337-1349. [PMID: 24773464 DOI: 10.1517/14656566.2014.913571] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
24 Gentile I, Buonomo AR, Borgia F, Zappulo E, Castaldo G, Borgia G. MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opin Investig Drugs. 2014;23:719-728. [PMID: 24666106 DOI: 10.1517/13543784.2014.902049] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
25 Sagnelli E, Santantonio T, Coppola N, Fasano M, Pisaturo M, Sagnelli C. Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment. Infection 2014;42:601-10. [DOI: 10.1007/s15010-014-0608-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]